Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

iRhythm Holdings (IRTC) Research & Development (2016 - 2026)

iRhythm Holdings has reported Research & Development over the past 12 years, most recently at $21.4 million for Q1 2026.

  • Quarterly Research & Development fell 0.75% to $21.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $84.4 million through Mar 2026, up 11.14% year-over-year, with the annual reading at $84.6 million for FY2025, 18.4% up from the prior year.
  • Research & Development was $21.4 million for Q1 2026 at iRhythm Holdings, up from $21.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $21.5 million in Q1 2025 and troughed at $10.5 million in Q1 2022.
  • The 5-year median for Research & Development is $16.3 million (2023), against an average of $16.7 million.
  • The largest YoY upside for Research & Development was 43.96% in 2024 against a maximum downside of 3.77% in 2024.
  • A 5-year view of Research & Development shows it stood at $12.7 million in 2022, then rose by 21.63% to $15.4 million in 2023, then rose by 23.77% to $19.1 million in 2024, then increased by 10.3% to $21.0 million in 2025, then increased by 1.48% to $21.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRTC's Research & Development are $21.4 million (Q1 2026), $21.0 million (Q4 2025), and $21.0 million (Q3 2025).